Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2003
03/05/2003EP1287157A1 Protein markers for pharmaceuticals and related toxicity
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287031A2 Polynucleotides encoding for polymorphic isoforms of the pthrp protein, the encoded proteins and their therapeutic applications thereof
03/05/2003EP1287030A1 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287017A1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
03/05/2003EP1286995A1 2,7-naphthyridine derivatives
03/05/2003EP1286992A1 Piperidyindoles as serotonin receptor ligands
03/05/2003EP1286989A2 Prodrug of an ice inhibitor
03/05/2003EP1286984A2 Method for the preparation of tetrahydrobenzothiepines
03/05/2003EP1286975A1 Biclyclic cyclohexylamines and their use as nmda receptor antagonists
03/05/2003EP1286971A1 (e)-7[4-(4-fluorophenyl)-6-isopropyl-2-mesylaminopyrimidin-5-yl]-(3r,5s)-dihydroxyhept-6-enoic acid
03/05/2003EP1286964A1 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
03/05/2003EP1286962A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
03/05/2003EP1286957A1 Diphenylmethane derivatives
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286697A2 Method for selectively inhibiting ghrelin action
03/05/2003EP1286693A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
03/05/2003EP1286691A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
03/05/2003EP1286690A2 Use of alpha-msh and epo for preventing or treating ischemic conditions
03/05/2003EP1286686A2 Methods for preventing strokes by inducing tolerance to e-selectin
03/05/2003EP1286673A2 Ligands of integrin receptors
03/05/2003EP1286670A2 Use of therapeutic benzamide derivatives
03/05/2003EP1286665A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
03/05/2003EP1286659A2 Macromolecular drug complexes and compositions containing the same
03/05/2003EP1140893B1 Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process
03/05/2003EP1115719B1 Novel amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
03/05/2003EP1042278B1 1,3-disubstituted ureas as acat inhibitors, and method of preparing thereof
03/05/2003EP0971692B1 Specific magnetosome, method for the production and use thereof
03/05/2003EP0966447B1 Small molecules useful in the treatment of inflammatory disease
03/05/2003EP0952829B1 Pharmaceutical composition of fenofibrate with high biological availability and method for preparing same
03/05/2003EP0928197B1 Use of proteins as agents against autoimmune diseases
03/05/2003EP0892791B1 N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
03/05/2003EP0892633B1 Use of inhibitors of the activity of retinoic acid for treating sensitive skin and/or acute damage induced by uv radiation
03/05/2003EP0835262B1 Method for the treatment of corticosteroid induced osteopenia
03/05/2003EP0822824A4 Method of pretreating viable tissue or cells to be contained within a semipermeable vessel
03/05/2003EP0791009A4 Modified neuropeptide y receptors
03/05/2003CN1400975A 嘌呤衍生物 Purine derivatives
03/05/2003CN1400968A Method for preparing alpha sulfonyl hydroxamic acid derivatives
03/05/2003CN1400908A Combinations comprising dipeptidylpepidase IV inhibitors and antidiabetic agents
03/05/2003CN1400904A Selective estrogen receptor modulators in combination with estrogens
03/05/2003CN1400902A Oral formulation comprising an inhibitor compound of the ileal bile transport and on HMG CO-A reductase inhibitor
03/05/2003CN1400871A Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability of undesired permeability of the
03/05/2003CN1400869A Inulin products with improved nutritional properties
03/05/2003CN1400018A Medicine for curing adiposis, diabetes and related diseases
03/05/2003CN1400016A Capsule for cleaning blood and reducing fat
03/05/2003CN1400015A Health-care product for curing diabetes and its preparation method
03/05/2003CN1400002A Medicine tea for curing diabetes and its preparation method
03/05/2003CN1399998A Chinese medicine prescription for reducing blood fat and dissolving thrombus
03/05/2003CN1399969A Production method of health-care food with auxiliary action for curing diabetos
03/05/2003CN1399968A Health-care food and its production method
03/05/2003CN1399966A Tieweikang for iron tonifying
03/05/2003CN1102598C Peptides derived from human heat shock protein 60, compositions and application thereof
03/05/2003CN1102573C Aryl or heteroaryl substd, 3,4-dihydroanthracene and benzo [1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivs having bioactivity of visual pigmentoid
03/05/2003CN1102399C Antilipemic blood circulation promoting xueluofu capsule
03/05/2003CN1102396C Production process of compound meilingzhihua health food series
03/05/2003CN1102394C Health care product containing lacteinand its preparing method
03/05/2003CN1102382C Preparation and methods for the treatment of T cell mediated diseases
03/05/2003CN1102351C Health care food having functions of reducing weight andpreventing cardiovascular disease and preparing process thereof
03/05/2003CA2421283A1 Novel mmp-2 derivatives for use as inhibitors of integrin .alpha.v.beta.3
03/04/2003US6528699 Inserting nucleic acid construct which comprises promoter, milk protein specific signal sequence; can use for treating diabetes and multiple sclerosis
03/04/2003US6528637 Fatty acid synthase mRNA binding protein
03/04/2003US6528543 Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea
03/04/2003US6528542 Adjustment concentration
03/04/2003US6528538 Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharamaceutical compositions and preparation process
03/04/2003US6528525 Amidocarboxylic acid derivatives
03/04/2003US6528522 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
03/04/2003US6528512 Cytokine specific binding protein;
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528508 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli
03/04/2003US6528507 Arginine salt of 3-(4-(2-(phenoxazin-10-yl)ethoxy) phenyl)-2-ethoxypropanoic acid
03/04/2003CA2400565A1 Biomodulated multiparticulate formulations
02/2003
02/28/2003WO2002020009A1 Medicinal compositions
02/28/2003CA2420951A1 Medicinal compositions
02/27/2003WO2003016549A2 Nucleic-acid associated proteins
02/27/2003WO2003016530A1 Novel protein and its dna
02/27/2003WO2003016351A2 N - cam related compounds modulating cell groth
02/27/2003WO2003016348A2 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
02/27/2003WO2003016335A2 Irreversible cysteine protease inhibitors of legumain
02/27/2003WO2003016291A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
02/27/2003WO2003016288A1 Fxr nr1h4 nuclear receptor binding compounds
02/27/2003WO2003016280A1 Nr1h4 nuclear receptor binding compounds
02/27/2003WO2003016276A2 3-substituted oxindole beta-3 agonists
02/27/2003WO2003016270A2 Selective estrogen receptor modulators
02/27/2003WO2003016267A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
02/27/2003WO2003016265A1 Cyclic compound and ppar agonist
02/27/2003WO2003015820A1 GnRH AGONIST COMBINATION DRUGS
02/27/2003WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine
02/27/2003WO2003015807A1 Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives
02/27/2003WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003WO2003015794A1 Methods and compositions for treating apoptosis associated disorders
02/27/2003WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
02/27/2003WO2003015781A1 Novel antidiabetic pharmaceutical compositions
02/27/2003WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
02/27/2003WO2003015774A1 Compounds effecting glucokinase
02/27/2003WO2003015772A1 Inhibitors of polyq-aggregation
02/27/2003WO2003015769A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments
02/27/2003WO2003015765A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
1 ... 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 ... 1298